Peters B S, Beck E J, Anderson S, Coleman D, Coker R, Main J, Migdal C, Harris J R, Pinching A J
Department of Immunology, St Mary's Hospital Medical School, London, U.K.
J Infect. 1991 Sep;23(2):129-37. doi: 10.1016/0163-4453(91)91987-9.
Among 347 AIDS patients seen at St Mary's Hospital, London between 1983 and 1989, cytomegalovirus (CMV) disease was observed in 75 (22%). Of these, 58 (77%) had CMV retinitis, 26 (35%) CMV colitis, and 12 (16%) had CMV infection diagnosed at other sites. Relapse occurred in 71%. A favourable response to the use of ganciclovir as induction therapy for CMV retinitis was observed in 92%. Relapse of CMV retinitis occurred in 54% at a median time of 97 days. Neutropenia was the most frequent and serious side-effect of ganciclovir, 76% patients having neutrophil counts less than 1.0 x 10(9)/l and 48% less than 0.5 x 10(9)/l at some stage of therapy. Thrombocytopenia was also common, and platelet counts of less than 50 x 10(9)/l occurred in 43% patients on ganciclovir. The concurrent use of zidovudine made the development of severe neutropenia and thrombocytopenia more likely. Median survival following the diagnosis of CMV disease increased from 5-8 months between 1984 and 1987, to over 12 months in 1988. Patients with CMV colitis had a worse prognosis than patients with CMV retinitis, with median survival of 4.5 and 7 months respectively. In conclusion, CMV is an important opportunist infection in AIDS and both the disease and its treatment cause considerable morbidity. Hence, it is important to develop more effective and less toxic forms of therapy for CMV infection.
1983年至1989年间,在伦敦圣玛丽医院就诊的347例艾滋病患者中,75例(22%)出现了巨细胞病毒(CMV)疾病。其中,58例(77%)患有CMV视网膜炎,26例(35%)患有CMV结肠炎,12例(16%)在其他部位诊断出CMV感染。71%的患者出现复发。92%的患者在使用更昔洛韦作为CMV视网膜炎诱导治疗时出现良好反应。CMV视网膜炎复发率为54%,中位复发时间为97天。中性粒细胞减少是更昔洛韦最常见和最严重的副作用,76%的患者在治疗的某个阶段中性粒细胞计数低于1.0×10⁹/L,48%的患者低于0.5×10⁹/L。血小板减少也很常见,使用更昔洛韦的患者中有43%的血小板计数低于50×10⁹/L。同时使用齐多夫定使严重中性粒细胞减少和血小板减少的发生更有可能。CMV疾病诊断后的中位生存期从1984年至1987年的5至8个月增加到1988年的超过12个月。患有CMV结肠炎的患者预后比患有CMV视网膜炎的患者更差,中位生存期分别为4.5个月和7个月。总之,CMV是艾滋病中一种重要的机会性感染,该疾病及其治疗都会导致相当高的发病率。因此,开发更有效且毒性更小的CMV感染治疗方法很重要。